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Abstract
Background: Activating mutations in one allele of an oncogene (heterozygous mutations) are widely believed to be
sufficient for tumorigenesis. However, mutant allele specific imbalance (MASI) has been observed in tumors and cell lines
harboring mutations of oncogenes.
Methodology/Principal Findings: We determined 1) mutational status, 2) copy number gains (CNGs) and 3) relative ratio
between mutant and wild type alleles of KRAS, BRAF, PIK3CA and EGFR genes by direct sequencing and quantitative PCR
assay in over 400 human tumors, cell lines, and xenografts of lung, colorectal, and pancreatic cancers. Examination of a
public database indicated that homozygous mutations of five oncogenes were frequent (20%) in 833 cell lines of 12 tumor
types. Our data indicated two major forms of MASI: 1) MASI with CNG, either complete or partial; and 2) MASI without CNG
(uniparental disomy; UPD), due to complete loss of wild type allele. MASI was a frequent event in mutant EGFR (75%) and
was due mainly to CNGs, while MASI, also frequent in mutant KRAS (58%), was mainly due to UPD. Mutant: wild type allelic
ratios at the genomic level were precisely maintained after transcription. KRAS mutations or CNGs were significantly
associated with increased ras GTPase activity, as measured by ELISA, and the two molecular changes were synergistic. Of
237 lung adenocarcinoma tumors, the small number with both KRAS mutation and CNG were associated with shortened
survival.
Conclusions: MASI is frequently present in mutant EGFR and KRAS tumor cells, and is associated with increased mutant
allele transcription and gene activity. The frequent finding of mutations, CNGs and MASI occurring together in tumor cells
indicates that these three genetic alterations, acting together, may have a greater role in the development or maintenance
of the malignant phenotype than any individual alteration.
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Introduction
Oncogenes may be activated by mutation, structural rearrange-
ment or gene copy number gains (CNGs) [1,2]. While activating
somatic mutations in one allele of an oncogene (heterozygous
mutation, ‘‘one hit’’) is generally believed to be sufficient to confer a
selective growth advantage on the cell [1], mutant allele specific
imbalance (MASI, Fig. 1a) has been observed in tumors and cell
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7464lines harboring oncogenic mutations. As early as 1991, we reported
that KRAS mutations in cancer cell lines frequently demonstrated
completeorrelativeMASI[3](Fig.1b).InApril2004justbeforethe
two initial major publications about activating mutations of
epidermal growth factor receptor (EGFR) gene appeared[4,5], we
examined a never smoker female with adenocarcinoma of the lung,
and found a nine base pair deletion mutation in exon 19 of the
EGFR gene (Fig. 1c). Even though the tumor had not been
microdissected, the mutant allele appeared to be in great excess.
More recently we noted the frequent presence of CNGs in tumor
cells having mutant forms of the same genes [6].
Recent genome-wide approaches, especially high resolution
single nucleotide polymorphism (SNP) arrays, enable evaluation of
dynamic chromosomal as well as focal changes of CNG and loss of
heterogeneity (LOH) with very high resolution. Within a few
years, these assays have identified several novel lesions with
amplification and/or LOH across several organs [7]. An
important identification by SNP array was that uniparental
disomy (UPD), which was originally described as a constitutional
mechanism during meiosis [8], was frequently observed in several
cancers [9,10,11,12]. UPD arises when an individual inherits two
copies of a particular chromosome from the same parent [8]. The
acquisition of UPD results in homozygosity for preexisting gene
mutations with selective retention of the mutated allele. Acquired
UPD in association with oncogenic mutations has been reported in
hematopoietic malignancies including FLT3 and WT1 mutations
in acute myeloid leukemia [10,13] and JAK2 mutations in
myeloproliferative disorders [14,15]. To date, all reports of
acquired UPD in solid tumors have been in association with the
‘‘two hit’’ inactivation of tumor suppressor genes [9,11,16].
EGFR pathway genes, including, EGFR, KRAS, BRAF, and
PIK3CA genes, are well-investigated oncogenes in many tumors
including lung, colorectal (CRC), and pancreatic cancers (PAC)
[6,17,18,19]. Activating RAS mutations, including KRAS, are the
most frequent oncogenic mutations present in human tumors,
detected in about 20% of non-small-cell lung cancer (NSCLC),
40% of CRC and over 90% of PAC [19]. BRAF and PIK3CA genes
are also activated by mutations in CRC [17,18,20] and
occasionally in lung cancers [21,22]. Activating mutations of
EGFR gene are present in 15–30% of NSCLC while they have
been rarely detected in other type of human cancers [23,24].
EGFR CNGs were also reported in NSCLC and may play a role in
response and survival to tyrosine kinase inhibitor therapy [6,25,26]
while KRAS CNGs have not been investigated in depth in clinical
tumors including NSCLCs. Taken together, the inter-relationship
between mutations, CNGs and MASI is complex. The goal of the
Figure 1. Mutant allele specific imbalance (MASI) and some earlier observations. a) types of MASI. Three major types of MASI may occur. b)
Complete MASI of KRAS gene as identified in 1991. We reported KRAS mutations in non-small-cell lung cancer (NSCLC) cell lines using restriction
fragment length polymorphism (RFLP) method which can digest only wild type (WT) allele. We made this figure using modified methodologies from
the original publication [3]. Three out of four KRAS mutant NSCLC lines showed homozygous mutations (complete MASI) of KRAS codon 12. NT, no
treatment of restriction enzyme; +, presence of treatment of restriction enzyme. c) Our first EGFR mutation (exon 19 deletion) showed that the mutant
allele was in great excess compared to the WT allele. WT, wild type.
doi:10.1371/journal.pone.0007464.g001
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relationships between mutations, CNGs and MASI, and to clarify
the biological and clinical significance of these oncogenic
alterations.
Materials and Methods
Frequency of homozygous mutation from the Sanger
Institute public database
We queried the zygosity status of 11 well-known and frequently
mutated genes including six tumor suppressor genes (TP53,
CDKN2A, PTEN, RB1, APC, and SMAD) and five oncogenes
(KRAS, BRAF, PIK3CA, NRAS, and EGFR) tested in 833 cell lines
from the database of the Cancer Genome Project, Sanger
Institute, Cambridge, UK (www.sanger.ac.uk). We limited our
examination to genes having relatively large numbers of mutations
(.30) but also included the EGFR gene (7 mutations) which forms
the basis of much of our work. Because of stromal cell
contamination in clinical tumor samples, we limited our
examination to tumor cell lines. We downloaded the free database
of mutational status and zygosity status for each gene (on April 8
th
2009). Zygosity status of each mutation was determined at the
Institute by manual examination of the sequencing electrophero-
grams (response to our query, Sanger #80248). We calculated the
frequency of homozygosity for each of the 11 genes and for the
entire oncogene or tumor suppressor groups.
Cell lines
We studied 114 tumor cell lines of lung cancer (n=85), CRC
(n=19) or PAC (n=10) origin. The details of each line are shown
in Table S1. The origins of the lung lines have already been
described [6,22]. We also investigated six human bronchial
epithelial cell lines (HBEC lines 2KT, 3KT, 5KT, 15KT,
17KT, and 21KT), which were initiated by us [27,28]. All CRC
and PAC lines were purchased from the American Type Culture
Collection (ATCC, Manassas, VA).
All cell lines were proven to have individual genetic origins by
the Powerplex 1.2 system (Promega, Madison, WI) and, when
available, corresponded with their original profiles as obtained
from the ATCC.
Tumor Samples
We studied 393 tumors of NSCLC (n=333) or CRC (n=60)
origin (Table S2a–d). DNAs from 269 NSCLC tumors from
patients undergoing surgical resection in Japan,the United States or
Australia having known EGFR or KRAS mutations and survival data
were selected from a larger set of previously studied resected
NSCLC [22,23,29]. In addition, we studied 45 DNA samples of
resected lung adenocarcinomas from British Columbia Cancer
Agency, Vancouver, Canada which had been studied by SNP
arrays. An additional 19 resected NSCLC cases were obtained from
Tartu University, Estonia. We also obtained 60 resected colorectal
cancer samples from the University of Texas Southwestern Medical
School Tissue Bank. Institutional Review Board permission and
written informed consent were obtained from all patients at each
collection site (the University of British Columbia - British
Columbia Cancer Agency Research Ethics Board, University of
Texas Southwestern Medical Center Institutional Review Board,
University of Texas MD Anderson Cancer center Institutional
Review Board, Ethics Review Committee on Human Research of
theUniversityofTartu,GraduateSchoolofMedicineand Schoolof
Medicine, Chiba University Ethical Committee, Graduate School
of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
University Ethics Committee, and The Prince Charles Hospital
Human Research Ethics Committee). The ethics committees of all
institutes approved the individual study. Finally, in order to study
tumor cell populations free of contaminating human stromal cells,
we studied subrenal capsule xenograft samples in SCID mice
directly established from primary human NSCLCs at British
Colombia Cancer Center, Vancouver, Canada [30].
DNA and RNA extraction
Genomic DNAs were isolated from cell lines, frozen tumors or
paraffin embedded tumors (in 19 cases from Tartu University) by
standard phenol-chloroform extraction [31] or by using DNeasy
Tissue Kit (QIAGEN, Valencia, CA, USA). Total RNAs were
extracted from cell lines using RNeasy Plus Mini Kit (QIAGEN).
cDNA was prepared by reverse transcription of RNA using
High-Capacity cDNA Reverse Transcription Kits (Applied
Biosystems, Foster City, CA, USA) according to the manufac-
turer’s protocol.
Detection of gene mutations by direct sequencing
We determined the mutational status of KRAS (mKRAS), BRAF
(mBRAF), PIK3CA (mPIK3CA) and EGFR (mEGFR) genes by direct
sequencing as described previously [22,23] and PCR conditions
are provided in Table S3. Briefly, genomic DNA or cDNA was
amplified by conventional PCR. All PCR products were incubated
with exonuclease I and shrimp alkaline phosphatase (Amersham
Bioscience Corp., Piscataway, NJ) and sequenced directly using
the Applied Biosystems PRISM dye terminator cycle sequencing
method (Perkin-Elmer Corp., Foster City, CA). All sequence
variants were confirmed by sequencing the products of indepen-
dent PCR reactions in both directions.
Quantification of relative ratio between mutant and wild
type alleles by direct sequencing
We quantified the relative ratios between mutant (mA) and wild
type (wA) alleles by direct sequencing to determine the percent of
the mutant allele (mA%) by three steps (Fig. 2a): 1) magnification
of electropherogram on computer screen using Finch TV software
(http://www.geospiza.com/finchtv.html) which can provide sharp
wave lines without boldness after maximization, 2) pixel based
wave peak heights measurement using a desktop ruler software,
MB-Ruler (http://www.markus-bader.de/MB-Ruler/), and 3)
calculation of mA%. For point mutations, we used the following
formula: mA%=Hmut./(Hmut+Hwt) (%), where Hmut is the
minimum distance between midpoint of mutant wave line at peak
and midpoint of baseline, and Hwt is the minimum distance
between midpoint of wild type wave line at peak and midpoint of
baseline. For deletion or insertion types of mutations, we used the
average of mA% of the first five different waves from the
beginning of mutations (Figure S1). We repeated the sequencing if
the first sequencing eletropherogram demonsrated high back-
ground noise.
Plasmids construction and plasmid mixture experiment
In order to validate mA% detected by direct sequencing, we
constructed each mutant or wild type pCR2.1-TOPO plasmid
from cell lines harboring 14 kinds of mutations using TOPO TA
cloning kit (Invitrogen, Carlsbad, CA, USA) and QIAprep
Miniprep Kit (QIAGEN). We mixed mutant plasmid with
corresponding wild type plasmid at various ratios and amplified
the mixed plasmid as a template of PCR using paired primer sets
for mutational analyses. PCR products were directly sequenced
and the mA% were determined by measurement of sequeincing
electropherograms. Finally, we confirmed the linearity between
Mutation and MASI of Oncogenes
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mA% detected by direct sequencing (Fig. 2b).
Quantification of relative ratio between mutant and wild
type alleles by sub-cloning
PCR products were cloned into pCR2.1-TOPO vector using
TOPO TA cloning kit (Invitrogen). About 20 clones (range15–25)
were randomly selected for sequencing using either M13 forward
primer or corresponding primers of each gene. mA% was
calculated as the percentage of mutant clones in the total number
cloned.
Quantification of relative ratio between mutant and wild
type alleles by restriction fragment length polymorphism
(RFLP)
Genomic DNAs from mutant samples were amplified by PCR
using corresponding primers which we have previously reported
(Table S3) [3,32,33]. While mA of EGFR exon 19 deletion type
mutations could be distinguished from wA based on 9 to 12 base
pairs differences, overnight digestion of PCR products was needed
for point mutations using appropriate enzymes which can
specifically digest wild type sequences (Figures S2a and b). After
12.5% polyacrylamide gel electrophoresis, the gel was stained with
ethidium bromide. Band intensity of the respective mA and wA
was calculated using Kodak Image Station 2000RT and Kodak
1D Image Analysis Software (Kodak, Rochester, NY) and mA%
was determined from these ratios. We also confirmed that multiple
control samples (wild type) were completely digested in every assay
(Figures S2a and b).
Analyses of copy number by quantitative PCR assay
CNGs of KRAS, EGFR, BRAF and PIK3CA genes were
determined by real-time quantitative PCR (qPCR) assay using
Power SYBRH Green PCR Master Mix (Applied Biosystems) as
previously reported (primer sequences are provided in Table S3)
[22]. Briefly, we used LINE-1 gene, which is the most abundant
autonomous retrotransposon in the human consisting of 17% of
the genome [34], as a reference gene for all copy number analyses.
Gene dosage of each target and reference gene was calculated
using the standard curve method. Relative copy number of each
sample was determined by comparing the ratio of target gene to
LINE-1 in each sample with the ratio of these genes in normal
human genomic DNA (EMD Biosciences, Darmstadt, Germany),
made from a mixture of human blood cells from six to eight
Figure 2. Homozygous mutations (complete MASI) of oncogenes are frequent. Quantitation of mutant allele (mA) by direct sequencing (a
and b). wA, wild type allele; WT, wild type; mA%, proportion of mutant allele. a) Calculation method of mA% in point mutations by sequencing
eletcropherogram is shown. b) An example of accuracy of mutant allelic quantitation (mA%) by measurement of sequencing electropherogram (KRAS
mutation: G12V, 35G,T; results of forward reading is shown). We performed similar experiments for 14 kinds of mutations of KRAS, BRAF, PIK3CA or
EGFR genes and confirmed the accuracy of mA% by measurement of sequencing electropherograms. F, forward sequencing; R, reverse sequencing c)
and d) Frequency of homozygous mutations of 11 well-described tumor related genes in 833 cancer cell lines collected at Cancer Genome Project,
Welcome Trust Sanger Institute (www.sanger.ac.uk/). As expected, homozygous mutations are frequent in six tumor suppressor genes (c). Those of
five oncogenes are also relatively frequent (d). MASI, mutant allele specific imbalance; The prefix m- means mutant.
doi:10.1371/journal.pone.0007464.g002
Mutation and MASI of Oncogenes
PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7464different donors, as a diploid control. Based on our previous study
[6], we defined CNG in cell lines as values greater than four.
Single nucleotide polymorphism (SNP) array and data
processing
Samples were analyzed using the Genome-Wide Human SNP
Array 6.0 platform (Affymetrix Inc., Santa Clara, CA) according
to the manufacturer’s directions. GeneChip Command Console
Software (GCOS) was used to generate feature extracted intensity
(.CEL) files which were subsequently processed using the Birdseed
v2 algorithm in Genotyping Console 3.0.2 to create genotype
(.chp) call files.
Analysis of copy number and allelic imbalance by SNP
array
Copy number and allele status were determined using Partek
Genomics Suite (Partek Inc, St. Louis, MO). All CEL files were
imported using the same default parameters. Copy number values
were generated by normalizing each sample’s probe set intensity to
that of a reference. For tumors, paired references were used
consisting of the normal lung tissue profile matching each patient.
For lung cancer cell lines, an unpaired, pooled reference generated
from the intensities of all 45 normal lung tissue profiles (those
matching the tumors described above) was used. Regions of copy
number gain and loss were then statistically detected using the
Hidden Markov Model (HMM) based segmentation method of the
software package with default parameters and the requirement of
at least 50 contiguous probe sets.
Regions of allelic imbalance were determined using the allele
specific copy number (AsCN) function of Partek. For paired analysis,
only heterozygous SNPs in the reference (matched normal lung
sample) were considered informative and the reference intensity for
copy number creation was the allele intensity in the normal sample.
In unpaired analysis, this reference intensity was taken as the average
allele intensity of all reference (45 normal lung samples, see above)
samples that were heterozygous for a given SNP. The ethnicity of all
patients is listed in Table S2. Proportion scores for each SNP were
then calculated and segmented in order to find regions of similar
status and segments with a mean proportion score for all SNPs in the
region .0.15 (as recommended by Partek) were considered
imbalanced. Finally, adjacent regions meeting this threshold of
imbalance were merged and the average proportion score calculated.
The segment displaying the highest degree of imbalance across a
chromosome arm(based on proportion score) is alsolisted for specific
examples. All SNP data was visualized using SIGMA
2 software
(http://www.flintbox.com/technology.asp?page=3716) [35].
mRNA expression of KRAS, EGFR, BRAF and PIK3CA genes
by qPCR assay
mRNA expression of each mutant gene was evaluated by real-
time qPCR of cDNA product. Primer sequencing and PCR
conditions areprovided in Table S3. As an internal control, we used
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. After
quantitation of each target and reference genes by the standard
curve method, relative expression was calculated to compare the
value of cell lines with the average value of HBEC 15 and 21 cell
lines (for NSCLCs lines) or the value of human adult normal colon
RNA (BioChain Institute, CA, USA) for CRC lines, respectively.
Ras activity by ELISA
Ras activity was evaluated using Ras GTPase Chemi ELISA
(Active Motif, CA) following the manufacturer’s protocol. Briefly,
cell lysates from cell lines were quantified using BSA Protein Assay
Kit (Pierce, IL). Glutathione-S-transferase (GST) fused to ras-
binding-domain (RBD) of Raf which can specifically bind only to
activated Ras was coated onto glutathione-coated microplates by a
one hour incubation. After washing, equal amounts of cell lysates
(45 mg) were applied and incubated for one hour. A primary
antibody which can detect H- and K-ras was added and incubated
for one hour. An hour incubation with a second antibody
conjugated to horseradish peroxidase (HRP) and developing
chemiluminescent reagents were used to detect activated Ras
binding to the plate. The luminescent intensity, which was
inversely proportional to the amount of activated Ras, was read
using FLUOstar OPTIMA (BMG LABTECH GmbH, Offenburg,
Germany). Each cell line was tested in duplicate. All values
presented are relative light units compared with mean value of two
HBEC lines that was arbitrarily assigned a value of one.
Estimation of tumor heterogeneity by SNP array
Tumor samples contain varying numbers of stromal and other
non malignant cells that may affect estimates of tumor cell gene
copy number and allelic imbalance. To estimate tumor DNA
content for clinical samples, we used a method adapted from Weir
et al [7]. Briefly, we determined the log2 ratios and LOH status for
each informative SNP in the tumor samples using dChip software
with default settings. Regions of hemizygous deletion (i.e. one copy
loss in diploid cells) in each sample were determined by identifying
SNPs that displayed copy number loss (tumor vs normal log2 ratio
#20.2) with concordant LOH. In order to identify the lost allele
in these regions, we then calculated allele-specific intensity ratios
using the aroma.affymetrix package in R [36]. Since the lost allele
in these regions has zero copies, any signal would be attributed to
contamination by normal cells (which have one copy of each
allele). Thus, this lost allele ratio represents the percent of normal
cells in the sample. For each sample, the median ratio of the lost
allele was then calculated for individual chromosomes and the
minimum of the medians was determined. This value was then
subtracting from one to determine the percentage of tumor cells in
each clinical sample.
Statistical analyses
The differences of significance among categorized groups were
compared using Chi-square or Fisher’s exact tests as appropriate
for univariate analyses. Univariate analyses of overall survival (OS)
were performed using the Kaplan-Meier method with a log-rank
test. All data were analyzed with GraphPad Prism 5 software
(GraphPad Software, San Diego, CA). All statistical tests were two-
sided and probability values ,0.05 were defined as being
statistically significant.
Results
Homozygous mutations (Complete MASI) of oncogenes
are frequent in tumor cell lines
For the 11 genes queried in the Sanger database, we identified a
total of 1436 mutations (1157 for tumor suppressor genes, 279 for
oncogenes) (Table 1, Fig. 2c and 2d). As expected, homozygous
mutations were frequent in six tumor suppressor genes (81%), with
the exception of APC, while the five oncogenes also had a relatively
high frequency of homozygous mutations (20%). However, the
frequency of homozygous mutations varied - being frequent in
KRAS or EGFR mutant lines but not with PIK3CA mutations. As
shown below, the true incidence of MASI is higher, as the Sanger
data base does not have quantitative copy number data for cell
lines.
Mutation and MASI of Oncogenes
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for four oncogenes (total of 75 mutations) (Table 1). We found a
mean incidence of 27%, range 0% for PIK3CA to 38% for KRAS.
The frequencies of homozygous mutations for EGFR (20%) and
BRAF (13%) were intermediate. Thus our findings are similar and
complementary to the information from the Sanger database.
Determination of relative ratio between mutant and wild
type alleles by direct sequencing
As described in the Methods Section, we determined the
relative proportions of mutant and wild type alleles (mA%) by
measurements of the direct sequencing eletropherograms. To
validate this approach, we applied it to mixtures of varying
percentages of wild type and mutant plasmids. The results of the
sequencing method were highly concordant with the actual
mixture percentage of mutant and wild type plasmids for all 14
mixture experiments for all four genes tested (R
2 value$0.95,
Fig. 2b and Table S4). Furthermore, mA% of subcloning of 48
mutant lines (R
2 value$0.87) and RFLP analyses of 38 mutant
lines (R
2 value$0.89) also showed good concordance with
electropherogram measurements (Figure S2c), demonstrating
the accuracy of latter assay. These results fully validate the
sequencing eletropherogram measurement as an accurate method
to determine mA%.
Estimation of tumor DNA content in clinical samples
We estimated tumor DNA content (% tumor DNA) from the
SNP array data as described in Methods for 45 lung adenocar-
cinomas. Two control NSCLC lines (100% tumor cells) had
estimated values of 89% and 95% of % tumor DNA while the
median value of the tumors was 57%, range 26 to 93%. For these
45 cases, we adjusted all copy number using the % tumor DNA.
Mutations and CNGs of KRAS, BRAF, PIK3CA, and EGFR
genes
Details of the gene mutations and CNGs in the cell lines
(n=114) and tumors (n=521) are provided in Tables S1, S2 and
S5. Without SNP array data, the presence of UPD in tumor
samples could not be determined. Because the results of cell lines
and tumors were similar, a combined summary is presented in
Fig. 3a. All KRAS, BRAF, and EGFR mutations were mutually
exclusive across different tumor types while some PIK3CA mutant
cases also harbored one of the other three mutations (Tables S1
and S2) as described previously [22,37,38].
For the three genetic alterations (mutations, CNGs or both)
each gene demonstrated a distinct pattern. Most of the alterations
in KRAS were mutations, with occasional CNGs or both. For
EGFR, CNGs were the most frequent alteration, although
mutations or both changes were present in prominent subpopu-
lations. For BRAF, mutations and CNGs showed nearly equal
frequencies, while both changes were rare. For PIK3CA, CNGs
without mutations were the most frequent change (Fig. 3a).
The different patterns of MASI
The relationships between of mA% (as determined by electro-
pherogram mesurement) and CNGs (as determined by qPCR) for
the mutant genes in 68 mutant lines including seven lines with
double mutations are shown in Fig. 3b. Three major patterns were
observed: 1) Balanced, having a mA: wA ratio (mA/wA) of about 1
(range 0.5 to 2) without CNG (i.e. – MASI not present); 2) MASI
with CNG, either complete [wA lost (mA/wA.9) or partial (mA/
wA.2)]; and 3) MASI without CNG (uniparental disomy; UPD),
due to complete loss of wA (mA/wA.9) and selective retention/
duplication of mA, respectively (Fig. 1a and 3b). Cases with UPD or
complete MASI with CNGs lie off the standard curve because they
lack the wA (Fig. 3b). A fourth pattern, reverse MASI, defined as
wild type allele specific imbalance (mA/wA,0.5) was present in
only one line (1%) having a mEGFR.
Gene specific analyses versus genome wide analyses
We evaluated MASI status in seven mKRAS and two mEGFR lines
using SNP arrays, and compared the results with MASI status
determined by gene specific assays (mA% by direct sequencing and
copy number by qPCR). Examplesofthesecomparisonsare shown in
Fig. 4. Gene specific analyses defined the seven mKRAS lines as one
balanced type, one having MASI with CNG and five having UPD.
Of the mEGFR lines, one had MASI with CNG and one had MASI
with borderline CNG. Of note, the results detected by SNP array
were completely concordant with those of the gene specific assays.
Individual oncogenes utilize different types of MASI
For our studies, determination of relative ratio between mA and
wA (mA%) of tumor samples (in contrast to cell lines) requires SNP
array analyses. As shown in Table S2b, we confirmed that there
was good concordance between CNGs as estimated by SNP and
qPCR methods.
For 45 adenocarcinomas having SNP array data, direct
sequencing detected a high frequency of KRAS (n=21, 47%) or
EGFR (n=14, 31%) mutations. We determined allelic imbalance
(AI) and CNGs of KRAS and EGFR genes using SNP data. The
percentage of tumor cell DNA in the samples was determined as
described previously and we used appropriately adjusted copy
numbers for further analyses. Because MASI frequencies in tumors
(asdetermined bySNPassays) and cell lines(asdeterminedbydirect
sequencing combined with qPCR) were similar (Table S6), we
combined the data from 35 mutant tumors and 68 mutant cell lines.
As shown in Fig. 5a and Table 2, the frequencies for MASI (of
all types) varied between individual oncogenes, being relatively
high for EGFR (75%) and KRAS (58%) and lower for BRAF (38%)
and PIK3CA (8%). The major type of MASI also showed gene
variation (Fig. 5b and Table 2). For KRAS, UPD were more
frequent than CNGs, while for EGFR the major type of MASI
found in tumors and cell lines was CNGs, with UPD present in a
minor subpopulation. For BRAF and PIK3CA the data were too
scant to come to conclusions.
Table 1. Homozygous mutations of oncogenes are frequent
in cancer cell lines.
Sanger Institute Our data
Genes
% of Homozygous
mutations*
% of Homozygous
mutations**
(No. of mutant lines) (No. of mutant lines)
Total 20 (279) 27 (75)
KRAS 36 (92) 38 (45)
BRAF 17 (65) 13 (8)
PIK3CA 6 (65) 0 (12)
NRAS 10 (50) - (-)
EGFR 29 (7) 20 (10)
*, Zygosity status was determined by manual examination of sequencing
electropherograms at Sanger institute; **, Homozygous mutations were
defined as percent of mutant allele by direct sequencing greater than 90%.
doi:10.1371/journal.pone.0007464.t001
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We determined AI in both wild type and mutant case for KRAS
and EGFR genes among the 45 lung adenocarcinomas with SNP
data. For all 45 cases, AI was frequent in KRAS (n=28, 56%) and
EGFR (n=18, 40%) (Table S2b). However, EGFR AI was signif-
icantly more frequent in mEGFR (71%) than wild type EGFR cases
(29%, P=0.008). By contrast, AI of KRAS was equally observed in
mKRAS (62%) and wild type KRAS (63%, Table 2). While EGFR AIs
in wild type EGFR cases were equally caused by CNG (50%) and
UPD (50%), all KRAS AIs in wild type KRAS cases were caused by
UPD.
Double mutations occur on the same chromosome (cis
mutations)
Second site (double) mutations in the same gene (two examples
each for EGFR and PIK3CA) were present in four cell lines (Table
S1). For all four cell lines they showed very similar mA% for both
sites (less than 3.5% difference) (Table S1), even though two
mutations of EGFR were detected by independent PCR reactions.
These findings suggested that in all four cases both mutations
occurred on the same parental chromosome and were in cis with
each other. For EGFR mutant cases, a common activating
mutation was associated with a second resistance associated
mutation (T790M) and these two mutations have been described
as usually or always being in cis [39,40].
MASI is present in xenografts
Subrenal capsule mice xenografts were directly established from
primary human NSCLCs. These samples have the following
advantage: 1) less manipulation than cell lines (close to clinical
samples), and 2) lack of human normal stromal contamination
[30]. We identified two KRAS or two EGFR mutations by cDNA
sequencing using primer sets specific for the human gene in four of
27 subrenal xenograft samples (Figure S3). We confirmed the
human specificity of our primers by lack of an amplicon using
cDNA from healthy non-manipulated mouse liver as template
(data not shown). Of note, three out of four mutant samples (two
KRAS and one EGFR mutations) showed over 90% of mA%.
The ratio of mutant: wild type allele is maintained after
transcription
To investigate whether CNGs were reflected in increased
transcriptional activity, we compared mRNA expression with copy
number for 70 mutant cell lines (with or without MASI). As shown
in Fig. 6a, there was good concordance between the results of the
two techniques, indicating that increased copy number was
accompanied by increased transcription.
We then investigated whether the increased mA% of MASI
lines were maintained after transcription. Using a subset of 35
mutant cell lines (with or without MASI), we compared the mA%
of genomic DNA with the values from cDNA (Fig. 6b). There was
almost perfect concordance between the values, indicating that the
ratios of mutant:wild type alleles in genomic DNA were faithfully
maintained after transcription.
Ras GTPase activity and KRAS MASI
We evaluated ras GTPase activity by ELISA for 36 cell lines
including 26 lung, five colorectal, three pancreatic cancer lines and
two HBEC lines (Figure S4). The linearity of the standard curve
Figure 3. The association between mutations, copy number gain (CNG) and mutant allele specific imbalance (MASI) of EGFR
pathway genes. a) The association between mutations and CNG of EGFR pathway genes in cell lines and tumors across organs. We combined the
data of cell lines and tumors because of similarity of both data sets. Mutations are more frequent than CNG in KRAS gene while CNG are more
frequent than mutations in other genes. CNG are significantly correlated with mutations in KRAS (P,0.0001) and EGFR (P,0.0001) genes (*). However,
mutations or CNGs of BRAF and PIK3CA genes are usually exclusive and rarely present together. b) The association between percent of mutant allele
(mA%) and copy number for 75 mutations in 68 mutant cell lines. Gray dotted line is the hypothetical curve of mutant allele specific amplification.
There were 36 mutations with MASI (48%), 38 with balanced (51%) and one with reverse MASI (1%). Thirteen mutant cell lines including mutant KRAS
(n=12) and BRAF (n=1) had uniparental disomy (complete MASI without CNG) and four lines (all mutant KRAS) had complete MASI with modest level
of CNG (copy number,9, black dotted circle). The prefix m- means mutant; mA%, proportion of mutant allele.
doi:10.1371/journal.pone.0007464.g003
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2=0.97, data not
shown). HBEC cultures and wild type tumor cell lines had
comparably low levels of activity (Fig. 6c). Both lines with KRAS
CNGs (without mutation) and those with balanced mutations
(without CNGs) had significant 11–12 fold increases in GTPase
activity. Cell lines having UPD (without CNGs) had a modest
(approximately 50%) increase compared to the balanced mutant
lines, although this increase was not significant. However mutant
lines having MASI with CNGs had a significantly increased mean
activity when compared to the other mutant groups.
EGFR MASI and in vitro sensitivity to gefitinib
We have previously reported the gefitinib sensitivity of NSCLC
lines [6]. Seven of the 10 EGFR mutant lines were sensitive at a
clinically achievable concentration (,1 mM). We correlated these
data with the presence or absence of MASI (Table S7). While six
out of seven sensitive cell lines (86%) harbored EGFR MASI, we
could not find a convincing relationship between gefitinib
sensitivity and EGFR MASI.
Figure 4. KRAS mutant allele specific imbalance (MASI) in lung cancer cell lines. (Left upper) Copy number and allelic imbalance status as
determined by SNP 6.0 arrays are depicted for representative cell lines with balanced and MASI patterns of KRAS mutant/wild type allele ratios. For
copy number, each blue dot represents an array element ordered by genomic position. Those shifted to the left of the middle line have decreased
copy number whereas those shifted to the right have increased copy number. For allelic imbalance, dashed lines represent regions with no imbalance
whereas solid lines represent those with imbalance. Thicker solid lines represent the region of maximum imbalance across the chromosome arm (see
methods). The genomic location of KRAS is indicated by the horizontal black line. (Left lower) Electropherograms of direct DNA sequencing with
mutant allele proportion (mA%, determined by electropherogram) and KRAS copy number (copy#, determined by quantitative PCR) are present in
the same cell lines used for SNP arrays. (Right lower) KRAS FISH in HCC1171 was performed using purified DNA from BAC clone RP11-1119I8
encompassing the KRAS gene (red signal) and CEP12-SpectrumGreen (Abbott Molecular, IL) as an internal control. Means of KRAS copy number are
21.6611.0 (standard deviation, SD) and those of CEP12 number are 3.761.2 (SD). Both SNP arrays and gene specific assays confirm that HCC2347
displays neutral KRAS copy number with no imbalance (mutant/wild type balanced) whereas HCC1171 and H2030 display imbalance (MASI) with
copy number gain (CNG) or uniparental disomy (UPD), respectively.
doi:10.1371/journal.pone.0007464.g004
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We determined the mutational status and copy numbers of
KRAS gene for 288 lung adenocarcinoma tumors including Non-
Asian (n=127) and Asian (n=161) populations obtained from five
different institutions and correlated the data with clinical and other
findings (Table 3). EGFR mutational status was available for 269
out of 288 cases [22,23,29]. We identified 57 KRAS mutations
(20%) and 29 KRAS CNGs (10%). As demonstrated previously in
Fig. 3a (for both cell lines and tumors), in this subset of tumors
KRAS CNGs were more frequent in mKRAS than in wild type
tumors. Because KRAS CNGs were closely associated with mKRAS,
KRAS CNGs demonstrated similar associations as have been
previously described for mKRAS (non-Asian ethnicity, smoking
history, and mutual exclusivity with EGFR mutations). Gender
differences were not significant for either mutations or CNGs.
We then evaluated the effect of KRAS alterations on clinical
outcome of 237 resected lung adenocarcinoma tumors which were
limited to stage I–III cases with survival data. Patients with mKRAS
tumors (P=0.2) or KRAS CNGs (P=0.1) alone had a trend to be
associated with poor prognosis. Tumors having both alterations,
while present in a small subpopulation (n=6), had worse prognosis
of borderline significance (P=0.04, Fig. 7).
We also identified 105 EGFR CNG in same subset of 269 lung
adenocarcinomas. EGFR CNGs were significantly more frequent
in never smokers, Asian ethnicity, were mutually exclusive with
KRAS mutations and occurred more frequently with EGFR
mutations than in wild type cases as previously described [26].
We were unable to investigate the effects of EGFR mutations and
CNGs on survival as data on TKI therapy was incomplete.
Discussion
Our earlier observations regarding homozygous mutations and
MASI led us to question the commonly held belief that
tumorigenesis requires biallelic inactivation for tumor suppressor
genes while the potent effects of dominant oncogenes preclude the
necessity of loss of the wild type allele product. We examined a
public database of mutations (Sanger Institute). We found, as
expected, that most inactivating mutations of tumor suppressor
genes were frequently accompanied by loss of the wild type allele.
However, our earlier observations on homozygosity of oncogenes
were confirmed by the finding that 20% of five activating
oncogene mutations were homozygous in cell lines derived from
multiple tumor types. As discussed below, the true incidence of
MASI is considerably higher as quatitative copy number data are
missing in the Sanger database. Thus MASI, while a long observed
and expected phenomenon for tumor suppressor genes, is also
present in an important subset of cells harboring mutant
oncogenes. Other published evidence supports this concept [41].
Detection of MASI of an oncogene requires three basic
determinations: 1) detection of an oncogenic mutation; 2) copy
number enumeration of the mutant gene in the tumor cells and 3)
determination of the relative ratio of the mutant: wild type allele
(mA%). Standard and widely accepted methods for the first two
determinations exist including direct sequencing for mutations,
and qPCR, FISH, aCGH or SNP analyses for CNGs [6]. For cell
lines (consisting of pure tumor cell populations) mA% can be
determined by subcloning or by the presence of homozygosisty of
the mutant allele. In order to avoid laborious and time intensive
subcloning, we determined that mA% could be accurately
estimated by measurements of the relative peak heights present
Figure 5. Different frequencies and mechanisms of MASI of EGFR pathway genes. MASI is equally frequent in mutant KRAS and EGFR genes
than others and PIK3CA MASI is rare (a). KRAS MASI is caused almost equally by uniparental disomy or copy number gain (CNG) while EGFR MASI is
mainly caused by CNG (b). The prefix m- means mutant. MASI, mutant allele specific imbalance.
doi:10.1371/journal.pone.0007464.g005
Table 2. Summary of allelic imbalance of EGFR pathway genes.
Subsets KRAS EGFR BRAF PIK3CA
Mutant Frequency of MASI Frequent Frequent intermediate Rare
Mechanisms of MASI UPD (+CNG) CNG CNG (+UPD) CNG
Wild type Frequency of AI in WT Equally frequent as MASI Rare - -
Mechanisms of AI UPD Rare (CNG) - -
AI, allelic imbalance; MASI, mutant allele specific imbalance; WT, wild type; UPD, uniparental disomy; CNG, copy number gain.
doi:10.1371/journal.pone.0007464.t002
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Proportion of mutant allele (mA%) determined by DNA sequencing electropherogram is significantly consistent with mA% by cDNA sequencing
using different sets of primers (b). c) KRAS alterations are related to ras GTPase activity. KRAS mutations or copy number gains (CNGs) alone are
related to high ras GTPase activity and the two molecular changes are synergistic. The prefix m- means mutant. HBEC, human bronchial epithelial cell;
WT, wild type; UPD, uniparental disomy; *, KRAS mutation with CNG versus Others; **, KRAS mutation with CNG versus either KRAS mutation or CNG;
***, either KRAS mutation or CNG versus WT.
doi:10.1371/journal.pone.0007464.g006
Table 3. The association between KRAS alterations and clinical and other genetic factors in 288 lung adenocarcinomas.
KRAS mut P Subsets (n) % KRAS CNG P Subsets % Mut or CNG P Subsets % Mut and CNG P Subsets %
All - - (288) 19.8 All - - 10.1 All - - 26.1 All - - 3.8
Gender NS Male (161) 21.7 Gender 0.08 Male 13 Gender NS Male 29.2 Gender NS Male 5.6
Female (127) 17.3 Female 6.3 Female 22 Female 1.6
Smoking* 0.0018 Never (101) 9.9 Smoking* 0.013 Never 4 Smoking* 0.0001 Never 12.9 Smoking* NS Never 1
Ever (184) 25.5 Ever 13 Ever 33.2 Ever 5.4
Ethnicity 0.0006 Non-Asian (127) 29.1 Ethnicity NS Non-Asian 13.4 Ethnicity ,0.0001 Non-Asian 37.8 Ethnicity NS Non-Asian 4.7
Asian (161) 12.4 Asian 7.5 Asian 16.8 Asian 3.1
EGFR mut** ,0.0001 Mutant (65) 0 EGFR mut** 0.008 Mutant 1.5 EGFR mut** ,0.0001 Mutant 1.5 EGFR mut** NS Mutant 0
WT (204) 25 WT 12.6 WT 32.4 WT 2.9
Mut, mutation; WT, wild type; CNG, copy number gain; NS, not significant; *, Smoking status was not available in three cases; **, Nineteen cases were not determined
mutational status and copy number of EGFR gene.
doi:10.1371/journal.pone.0007464.t003
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detection. While mA% could be determined accurately in cell lines
by these simple techniques, tumor samples present a much greater
problem because of contamination with highly variable percent-
ages of non-malignant cells. Reports of molecular studies often
provide estimates of the percentage of tumor cells by histologic
examination, but these are usually performed rapidly and are
relatively inaccurate. In addition, because of the frequent presence
of tumor cell polyploidy, most genetic analyses require determi-
nation of the percentage of tumor DNA in the examined sample,
rather than the percentage of tumor cells. For our studies, we used
SNP array data for determinations of tumor cell DNA percent-
ages. While this approach has been used by others [7], we refined
the methodology. We found a mean value of 57% tumor DNA in
the samples having SNP data, with a wide range of values. We
arbitrarily used a slightly more conservative estimate for tumor cell
DNA of 50% for the tumor samples lacking SNP data. While we
used such estimates for copy number determinations in tumors,
recognition of tumor homozygosity, including UPD, was limited to
the tumor subsets with SNP data.
Four types of inter-relationships between mA and wA were
found: a) balanced type, with mutant: wild type allele ratio of
approximately one (MASI not present); b) MASI (either partial or
complete) with CNG; c) uniparental disomy (complete MASI
without CNG); and d) reverse MASI (wild type allele increased
relative to mutant allele). For 75 mutations (in four genes) present
in 68 cell lines the overall incidence of MASI was 48%, while only
a single example of reverse MASI was identified (p,0.0001). Thus
allelic imbalance almost invariably targets the mutant allele. Our
previous observations regarding allelic imbalance (obtained by a
variety of techniques including subcloning) are consistent with our
present findings [3,6]. While MASI was convincingly demonstrat-
ed in cell lines the true incidence in tumors could only be
determined with accuracy for the subset of lung tumors having
SNP array data and mutational status of the KRAS and EGFR
genes. The incidences of MASI in lung cancer cell lines and
tumors for these two genes were not significantly different.
However, the incidences of MASI for individual oncogenes
showed differences, with high frequencies for EGFR and KRAS,
intermediate for BRAF and low for PIK3CA. These differences may
reflect variations in the oncogenic potential of the individual gene
mutations. The frequencies of the two major forms of MASI also
demonstrated individual gene differences. For EGFR and BRAF,
the most frequent type was MASI with CNGs, while for KRAS, the
frequencies of MASI with CNGs and UPD were similar.
While mutations of the KRAS and EGFR genes and CNGs of the
EGFR gene are well described [6,19,25,26,29], the literature
regarding KRAS CNGs in human tumors is sparse [7,42]. While
less common than mutations in the present study, KRAS CNGs
were relatively frequent. Of interest, KRAS CNGs showed the
same clinico-pathological associations as those previously de-
scribed for KRAS mutations – relationship to smoking status, non-
Asian ethnicity and mutual exclusivity with EGFR mutations [29].
While inherited UPD is associated with developmental
disorders. the role of acquired UPD in cancer development is
poorly understood [12]. Although UPD has been reported to be
related to inactivation of tumor suppressor genes, its presence with
activating oncogenic mutations has rarely been described in
tumors. To date, UPD has been mainly reported in hematopoietic
malignancies for a few oncogenes such as JAK2 [14]. Its incidence
and role in solid tumors is largely unknown, although, as
previously pointed out, this reflects the limits of our prior
technology [12]. As discussed previously, homozygosity of tumor
oncogenes in cancer cell lines is frequent, although the available
information did not permit the distinction between MASI with
CNGs or UPD as the mechanism. Using gene-specific and
genome-wide approaches we found that UPD was frequent for
three EGFR pathway genes, especially for KRAS gene (data for
PIK3CA mutations were too sparse for evaluation). Relatively little
data exists in the literature for KRAS CNGs in human tumors.
Furthermore, KRAS homozygosity was observed independent of
mutational status as previously described [43]. The wild type allele
of KRAS can also inhibit lung carcinogenesis in mice [44],
providing a possible explanation for the frequent finding of UPD
with mutant and wild type oncogenes.
MASI has apparent biological and clinical significance. MASI at
the genomic level was precisely maintained after transcription.
While mutations, CNGs and allelic imbalance of mA and wA may
all contribute to tumorigenesis, combinations of the three events
may be more effective than any single event. Evidence for this
concept was provided by our finding that the combination of
mutation and CNGs acted synergistically to enhance ras GTPase
activity. A recent report found that all KRAS mutations did not exert
an equal effect on tumor cells [42]. Cancer cell lines harboring
KRAS mutationscouldbebroadlydividedintoKRAS-dependent and
KRAS-independent groups. The vast majority of KRAS-dependent
lines exhibited focal KRAS CNGs, in contrast to KRAS-independent
lines. This study provides further evidence that the combination of
KRAS mutations and CNGs act synergistically. Our previous
findings that EGFR mutations were associated with tumor initiation
while EGFR CNG might be more regarded as a tumor progression
event, provide further evidence of their co-operative role in
tumorgenesis [45]. Understanding the mechanism of MASI could
elucidate new understandings of tumor biology and may contribute
to the development of rational targeted therapies.
MASI in its various forms is frequently present in mutant EGFR
and KRAStumor cells, and is associated with increased mutant allele
transcription and gene activity. The frequent finding of mutations,
copy number gains and MASI occurring together in tumor cells
indicates that these three genetic alterations, acting together, may
have a greater role in the development or maintenance of the
malignant phenotype than any individual alteration.
Supporting Information
Table S1 a) Mutant cell lines of KRAS, EGFR, BRAF, and/or
PIK3CA genes (n=68) mA%, mutant allele proportion (%); *, cell
Figure 7. The effect of KRAS mutations and copy number gain
(CNG) on clinical outcome in 237 lung adenocarcinomas. The
effect of 1) KRAS mutations (without CNG), 2) KRAS CNG (without
mutations), 3) both KRAS mutations and CNG, and 4) others (without
KRAS mutations and CNGs) on clinical outcome is shown. Tumors
having both alterations indicate worse prognosis with borderline
significance than all others (P=0.04). The prefix m- means mutant.
doi:10.1371/journal.pone.0007464.g007
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both BRAF and PIK3CA mutations; ***, blanked values are mA%
of second mutations of same gene (D549N for PIK3CA and
T790M for EGFR)(For EGFR DNA sequence, we performed
independent PCR reaction to evaluate mA% of primary and
second mutations). b) Wild type cell lines of KRAS, EGFR, BRAF,
and PIK3CA genes (n=46)
Found at: doi:10.1371/journal.pone.0007464.s001 (0.04 MB
XLS)
Table S2 a) Summary of 288 lung adenocarcinomas from five
institutes b) Summary of 45 lung adenocarcinomas with SNP array
data c) The association between KRAS and EGFR alterations and
clinicopathological factors in 45 lung adenocarcinomas with SNP
*, P value was calculated between Gain and Neutral; **, P value
was calculated between Never smoker and Ever smoker. d)
Summary of 60 colorectal cancer tumors
Found at: doi:10.1371/journal.pone.0007464.s002 (0.17 MB
XLS)
Table S3 a) Primer sequences for DNA sequencing b) Primer
sequences for cDNA sequencing *, These primers were also used
to detect KRAS or EGFR mutations in subrenal capsule mice
xenografts of primary human NSCLCs because these primers are
specific for human origin and no PCR product are amplified from
mouse cDNA as PCR template. c) Primer sequences for restriction
fragment length polymorphism *, The substitution of third letter in
KRAS codon 61 (limited to CAT or CAC mutation) can change
representative amino acid (Gltamine to Histysine). d) Primer
sequences for copy number analyses by quantitative PCR (qPCR)
assay e) Relative mRNA expression analyses by qPCR
Found at: doi:10.1371/journal.pone.0007464.s003 (0.03 MB
XLS)
Table S4 The accuracy of proportion of mutant allele (mA%) of
direct sequencing was evaluated by 14 kinds of plasmids mixture
experiment. We mixed mutant plasmid with corresponding wild
type plasmid at various ratios (5 to 7 points) and amplified the
mixed plasmid as a template of PCR. PCR products were directly
sequenced and the mA% were determined by measurement of
sequeincing electropherograms. Finally, we confirmed the linearity
between the actual mixed proportion of mutant and wild type
plasmids and mA% detected by direct sequencing. The results of
the sequencing method were highly concordant with the actual
mixture percentage of mutant and wild type plasmids in all 24
trend lines for four genes tested (R2 value.0.95).
Found at: doi:10.1371/journal.pone.0007464.s004 (0.02 MB
XLS)
Table S5 CNG, copy number gain; Both, cases with both
mutations and CNGs; NS, not significant (P.0.1); *, 314 tumors
were analyzed because of lack of mutational and copy number
data of EGFR gene in 19 Estonia cases; **, data were combined
current study and our previous studies - Yamamoto et al (Cancer
Res 68: 6913–6921) and Gandhi et al (PLoS ONE 4: e4576).
Found at: doi:10.1371/journal.pone.0007464.s005 (0.02 MB
XLS)
Table S6 CRC, colorectal cancer; PAC, pancreatic cancer;
MASI, mutant allele specific imbalance; UPD, uniparental disomy;
CNG, copy number gain; *, limited to 45 lung adenocarcinomas
with SNP data; **, because SNP array can not distinguish between
MASI and reverse MASI and because incidence of reverse MASI in
cell lines is low, we defined tumors harboring allelic imbalance with
CNG as MASI with CNG.
Found at: doi:10.1371/journal.pone.0007464.s006 (0.02 MB
XLS)
Table S7 All other 35 cell lines tested (except for 3 EGFR or
HER2 copy number gain cell lines) were resistant for gefitinib
(IC50.10 mM) (Gandhi et al: PLoS ONE 4: e4576)
Found at: doi:10.1371/journal.pone.0007464.s007 (0.03 MB
XLS)
Figure S1 Calculation method of mutant allele proportion
(mA%) for deletion (or insertion) type of mutations is shown. The
average of mA% of the first five different waves from the
beginning of mutations is calculated.
Found at: doi:10.1371/journal.pone.0007464.s008 (0.42 MB PPT)
Figure S2 We performed restriction fragment length polymor-
phism (RFLP) method to quantify mutant allele (Figures S2a and
b). Examples for two types of mutations (KRAS codon 12
mutations and EGFR exon 19 deletion type mutations) are shown.
Percent of mutant allele (%mA) detected by measurement of
sequencing electropherogram has good concordance with %mA
detected by subclonig and RFLP methods (Figure S2c).
Found at: doi:10.1371/journal.pone.0007464.s009 (0.59 MB PPT)
Figure S3 Mutant allele specific imbalance (MASI) can be
observed in mice xenograft samples. Complete MASI is present in
xenogragts established from patients with stage Ib to IIIa.
Found at: doi:10.1371/journal.pone.0007464.s010 (0.16 MB PPT)
Figure S4 Ras GTPase activity in 36 cell lines is shown. MASI,
mutant allele specific imbalance; WT, wild type; CNG, copy
number gain; HBEC, human bronchial epithelial cell; The prefix
m- means mutant.
Found at: doi:10.1371/journal.pone.0007464.s011 (0.18 MB PPT)
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